Trial Information

Summary: Clinical trial to test a study drug in adults and children with impetigo or secondarily infected traumatic lesions (SITL)

The primary objective of this study is to compare the effectiveness, safety, and tolerability of TD1414 2% Cream with Bactroban® (mupirocin) 2% Cream in adults and children with impetigo or secondarily infected traumatic lesions (SITL).

Study drug and study procedures will be made available to you at no cost.

To qualify, you must:

• Be at least 2 years old
• Have impetigo: Less than 10 discrete lesions or
• Have secondarily infected traumatic lesions (SITL) not exceeding 10 cm or (approximately 4 inches) in length (or for people younger than 18 years 2% of body surface area, i.e. roughly equivalent to size of two palms).

You will not qualify if you:

• Are pregnant or breast-feeding
• Have active (systemic) infection
• Have an infected human or animal bite
• Have participated in a clinical or device trial within the past 30 days

If you would like to learn more about participating in this study, please send an e-mail message using the form below.